Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Susan Moir · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $361,442 — In 2024, we conducted studies on COVID-19 by focusing on antibody and B-cell responses following multiple exposures to SARS-CoV-2 through infection and/or vaccination and contributed to studies addressing immune response to SARS-CoV-2 vaccination in people living with HIV (PLWH) or comparing respons…
Anthony Drew McDougal · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $77,284 — PROJECT SUMMARY: An organism's capacity to develop and grow is heavily dependent on its ability to organize various aspects of structure, ranging from G-actin to F-actin, cross-linked filaments, F-actin networks, and multicellular networks—in short, coordinate structure at multiple levels of order. …
Ursula Buchholz · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $227,201 — We previously constructed a first-generation construct called HPIV3-EbovZ GP, in which the complete genome of the JS strain of HPIV3 was modified by the addition of the Ebov GP gene in the third gene position, between the HPIV3 P and M genes. The JS strain is thought to be an attenuated HPIV3, based…
Jason Elinoff · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2024 · $194,017 — Primary human pulmonary artery and lung microvascular ECs express low levels of ACE2, TMPRSS2, and CD209L but high levels of NRP1. In contrast to lentiviral particles pseudotyped with the wild-type Wuhan variant, SARS-CoV-2 pseudovirus expressing the D614G spike protein variant successfully entered …
JAY A BERZOFSKY · DIVISION OF BASIC SCIENCES - NCI · 2024 · $1,300,408 — In vivo vaccine studies in macaques and hamsters: Rhesus macaques have been primed IM with S1 spike protein in different adjuvants and boosted systemically with spike in alum or mucosally intranasally with spike in nanoparticles (NPs) with IL-15 and TLR ligand adjuvants. We have found and published …
Yihong Ye · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2024 · $711,485 — Proteinaceous inclusions termed Lewy bodies (LBs) are a classical hallmark of Parkinson's disease (PD). The primary component of these inclusions is alpha-synuclein (a-syn), a protein with an intrinsic propensity to misfold and aggregate. In PD patients, alpha-syn inclusions first observed in the ol…
Manu Platt · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · 2024 · $365,276 — In year two of the MATRICES lab, now that we have been up and running with equipment, focus shifted to hiring and developing our scientific workforce to conduct our studies on sickle cell disease, proteolytic networks and tissue remodeling, and cancer metastasis. We currently have 3 postbaccalaurea…
Steven Holland · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $3,147,878 — The major activities of this research project in the past have centered around using our optimized methods and procedures for imaging rhesus macaques, NZW rabbits, and common marmosets on PET/CT scanners while conducting a variety of chemotherapy and basic immunology experiments in Mtb models. We ha…
Todd Jason Green · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2024 · $352,866 — PROJECT SUMMARY Patients receiving organ transplants have the risk of organ rejection due to mismatched human leukocyte antigens (HLA). Though organ recipients are screened for pre-formed anti-HLA antibodies (HLA-Abs) and are cross-matched using donor cells and recipient serum prior to transplantati…
Florian Krammer · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $626,637 — The SARS-CoV-2 pandemic represents an exceptional public health crisis highlighting the need for better understanding of the mechanisms controlling broadly protective immune responses and generating vaccine candidates able to elicit such responses. The program project entitled “Programming Long-last…
GEORGE Georgiou GEORGIOU · WASHINGTON UNIVERSITY · 2024 · $359,802 — ABSTRACT – CORE C Core C will be responsible for the in-depth determination of the molecular composition, temporal dynamics and functional properties of the antibodies that comprise the polyclonal response to influenza HA or to SARS-CoV2 S in peripheral blood and in the respiratory track, following …
Rafi Ahmed · EMORY UNIVERSITY · 2024 · $280,751 — ABSTRACT/SUMMARY: Single-cell genomic technology has rapidly transformed modern immunology. In relatively few short years, single-cell RNA sequencing has become near ubiquitous, primarily due to the availability of robust commercial platforms. The ability to combine multiple forms of information sim…
Andrew S. Pekosz · JOHNS HOPKINS UNIVERSITY · 2024 · $126,658 — JH-EPICS Virology Resource Core (VRC) Summary The Johns Hopkins Excellence in Pathogenesis and Immunity Center for SARS-CoV-2 (JH-EPICS) aims to systematically analyze the innate, T cell, and antibody responses that either protect or cause pathology during SARS-CoV-2 infection. In order to accuratel…
Cecilia Maria Leal · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · 2022 · $397,651 — PROJECT SUMMARY RNA therapeutics hold great promise for the treatment of a number of diseases significantly impacting human health, such as chronic infections, genetic disorders, certain cancers, and presently COVID-19. The leading RNA delivery vehicles approved by the FDA, as well as being consider…
Ann Scheck McAlearney · OHIO STATE UNIVERSITY · 2022 · $439,659 — Despite robust advances in vaccine technology and therapeutic intervention, the COVID-19 pandemic continues to impact our world both through disease-associated morbidity/mortality and its influence on economic stability and growth. Cancer patients (especially those receiving active immune suppressiv…
Richard B Kennedy · MAYO CLINIC ROCHESTER · 2022 · $757,630 — ABSTRACT The broad long-term goal of this application is to identify innate and T helper (Th) cell transcriptomic signatures of immune response and further our understanding of sex-dependent human immune responses to two unique influenza A/H3N2 vaccines in a population of older adult males and femal…
CHRISTOPHER A BENEDICT · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2022 · $615,063 — Summary Cytomegalovirus (CMV, a b-herpesvirus) establishes a persistent infection that is endemic in humans and mice. CMV causes acute clinical disease only if immunity is naïve or compromised, exemplifying how coevolution with its host over millennia has resulted in a largely non-pathogenic détente…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2022 · $3,420,035 — Neutralizing antibodies are likely to be required for an effective HIV-1 vaccine. However, few candidate vaccines efficiently elicit broadly neutralizing antibodies (bNAbs) following vaccination. Recently, the VRC working group has elicited fusion peptide-directed bNAbs in guinea pigs and non-human …
Fredrick Heath Damron · WEST VIRGINIA UNIVERSITY · 2022 · $833,885 — PROJECT SUMMARY Pertussis is a respiratory disease caused by the obligate human pathogen Bordetella pertussis. Two generations of pertussis vaccines have been developed and licensed: whole cell pertussis (DTP) and acellular pertussis (DTaP/Tdap). Pertussis was thought to be a disease of the past but…
Xiang Gao · ONCOTRAP, INC. · 2022 · $299,128 — Project Summary/Abstract Severe COVID-19 patients who develop acute respiratory distress syndrome (ARDS) and multiple organ failures share a hyperinflammatory cytokine/chemokine expression profile. This clinical observation resembles the cytokine release syndrome (CRS) which was the leading cause of…